# LBL-034

Source: https://onco.cc/drugs/lbl-034/  
OnCo record `lbl-034` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LBL-034 is an experimental bispecific T-cell engager from Nanjing Leads Biolabs, in phase 2 trials for multiple myeloma.

## Summary

LBL-034 is a bispecific T-cell engager (2:1 format) from Nanjing Leads Biolabs. A T-cell engager with two binding sites for GPRC5D and one for CD3 that directs T cells to GPRC5D-positive myeloma cells. Its furthest stage is phase 2, for multiple myeloma. ClinicalTrials.gov registers it in one study linked below. Phase I/II trial in relapsed/refractory multiple myeloma in China (NCT06049290, recruiting). FDA Orphan Drug (Oct 2024) and Fast Track (Jan 2026) per company. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: LBL-034
- Modality: Bispecific T-cell engager (2:1 format)
- Mechanism: A T-cell engager with two binding sites for GPRC5D and one for CD3 that directs T cells to GPRC5D-positive myeloma cells.

## Sources

- Nanjing Leads Biolabs: leadsbiolabs.com: https://www.leadsbiolabs.com/_nuxt/C0xAGIJr.js
- Nanjing Leads Biolabs: leadsbiolabs.com: https://www.leadsbiolabs.com/_nuxt/C0xAGIJr.js
- ClinicalTrials.gov: trials of LBL-034: https://clinicaltrials.gov/search?intr=LBL-034

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- targets: [CD3](https://onco.cc/targets/cd3/), [GPRC5D](https://onco.cc/targets/gprc5d/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)
- trials: [A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma](https://onco.cc/trials/nct06049290/)

---
JSON: https://onco.cc/api/v1/entities/lbl-034.json